based on 4 analysts
50.00%
Buy
50.00%
Hold
0.00%
Sell
Based on 4 analysts offering long term price targets for Glaxosmithkline Pharmaceuticals Ltd. An average target of ₹2914.5
Source: S&P Global Market Intelligence
Glaxosmithkline Pharmaceuticals Ltd price forecast by 4 analysts
Upside of20.84%
High
₹3250
Target
₹2914.50
Low
₹2550
Glaxosmithkline Pharmaceuticals Ltd target price ₹2914.5, a slight upside of 20.84% compared to current price of ₹2411.8. According to 4 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Glaxosmithkline Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:18.09%
Forecast
Actual
Including amortisation and stock based compensations
Glaxosmithkline Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:66.24%
Forecast
Actual
Source: S&P Global Market Intelligence
Day's Low
Day's High
52 Week's Low
52 Week's High
Returns % | |
1 Month Return | -8.31 % |
3 Month Return | -18.08 % |
1 Year Return | + 43.2 % |
Market Stats | |
Previous Close | ₹2,369.65 |
Open | ₹2,389.00 |
Volume | 2.89L |
Upper Circuit | - |
Lower Circuit | - |
Market Cap | ₹40,143.30Cr |
P/E Ratio | 51.66 |
PEG Ratio | 5.33 |
Market Cap | ₹40,143.30 Cr |
P/B Ratio | 18.45 |
EPS | 34.83 |
Dividend Yield | 1.65 |
Sector | Pharmaceuticals |
ROE | 36.83 |
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
---|---|---|---|---|---|---|
BUY | ₹40,143.30 Cr | 9.01% | 0.56 | ₹589 Cr | ₹3,453 Cr | |
BUY | ₹13,994.64 Cr | -2.57% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
BUY | ₹71,484.51 Cr | 35.55% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
HOLD | ₹94,993.52 Cr | 53.94% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
BUY | ₹57,618.74 Cr | 23.66% | 0.53 | NA | NA |
Organisation | Glaxosmithkline Pharmaceuticals Ltd |
Headquarters | |
Industry | Pharmaceuticals |
E-voting on shares | Click here to vote |
Key events for Glaxosmithkline Pharmaceuticals Ltd
In Q2FY25, Glaxo Pharma surpassed expectations, driven by robust growth in specialty and pediatric vaccine segments, despite challenges in generics. Management anticipates continued momentum in pediatric vaccines, with a 13% YoY increase in the first half of FY25.
GSK Celebrates 100 Years in India - 12 Nov, 2024
GSK marks a century in India, reflecting on its journey from antibiotics to vaccines. The company emphasizes innovation and adaptation in a challenging ecosystem.
GSK Pharma Declares Special Interim Dividend - 04 Nov, 2024
GSK Pharma has set November 7, 2024, as the record date for a special interim dividend of ₹12 per equity share, reflecting its strong financial position and commitment to shareholders.
GlaxoSmithKline Announces Special Interim Dividend - 03 Nov, 2024
GlaxoSmithKline Pharmaceuticals Ltd's Board has recommended a special interim dividend of Rs. 12 per share. The company reported a 5% increase in quarterly revenue, surpassing Rs 1000 crores, and a 15% rise in profit after tax to Rs 249 crores. For the half-year ending September 30, 2024, revenue grew by 7%, with EBITDA margins at 30%. This announcement coincides with the company's centenary year in India.
GSK Pharma Reports Strong Q2 Earnings and Dividend - 30 Oct, 2024
GlaxoSmithKline Pharmaceuticals reported a 5.53% revenue increase and a 15.59% net profit growth in Q2 FY25. The stock surged over 3% following the announcement of a special interim dividend of Rs 12 per share, reflecting strong performance and market confidence.
GlaxoSmithKline Reports Strong Q2 Growth and Dividend - 29 Oct, 2024
GlaxoSmithKline Pharmaceuticals announced a 16% increase in Q2 net profit to Rs 252 crore, driven by robust sales. The company declared a special interim dividend of Rs 12 per share, celebrating its centenary year in India.
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
Revenue Rich
Revenue is up for the last 2 quarters, 850.29 Cr → 1.05K Cr (in ₹), with an average increase of 19.0% per quarter
FII Holding Up
Foreign Institutions have increased holdings from 4.02% to 4.36% in Sep 2024 quarter
Profit Spike
Netprofit is up for the last 2 quarters, 182.33 Cr → 252.5 Cr (in ₹), with an average increase of 27.8% per quarter
MF Holding Up
Mutual Funds have increased holdings from 4.71% to 4.98% in Sep 2024 quarter
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 128.6% return, outperforming this stock by 77.8%
Promoter Holding Unchanged
Promoters holdings remained unchanged at 75.00% of holdings in Sep 2024 quarter
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 62.6% return, outperforming this stock by 19.4%
Retail Holding Down
Retail Investor have decreased holdings from 13.48% to 13.30% in Sep 2024 quarter
Price Dip
In the last 1 month, GLAXO stock has moved down by -8.3%
Investors | Holdings % | FY Quarter | 3M change |
---|---|---|---|
Promoter Holdings | 75% | 0.00 | |
Foreign Institutions | 4.36% | 8.59 | |
Mutual Funds | 4.98% | 5.75 | |
Retail Investors | 13.3% | ||
Others | 2.36% |
Glaxosmithkline Pharmaceuticals Ltd in the last 5 years
Lowest (-81.64x)
December 28, 2020
Today (51.66x)
November 22, 2024
Industry (54.77x)
November 22, 2024
Highest (333.07x)
September 15, 2020
Glaxosmithkline Pharmaceuticals Ltd’s net profit jumped 16.09% since last year same period to ₹252.50Cr in the Q2 2024-2025. On a quarterly growth basis, Glaxosmithkline Pharmaceuticals Ltd has generated 38.49% jump in its net profits since last 3-months.
Read More about Earnings ResultsIn the quarter ending September 2024, Glaxosmithkline Pharmaceuticals Ltd has declared dividend of ₹12 - translating a dividend yield of 1.82%.
Read More about DividendsBearish
Neutral
Bullish
Glaxosmithkline Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) share price today is ₹2411.8
Glaxosmithkline Pharmaceuticals Ltd is listed on NSE
Glaxosmithkline Pharmaceuticals Ltd is listed on BSE
PE Ratio of Glaxosmithkline Pharmaceuticals Ltd is 51.66
PE ratio = Glaxosmithkline Pharmaceuticals Ltd Market price per share / Glaxosmithkline Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is 2.89L.
Today’s market capitalisation of Glaxosmithkline Pharmaceuticals Ltd(GLAXO) is ₹40143.3Cr.
Glaxosmithkline Pharmaceuticals Ltd(GLAXO | Price |
---|---|
52 Week High | ₹3088 |
52 Week Low | ₹1577 |
Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2411.8. It is down -21.90% from its 52 Week High price of ₹3088
Glaxosmithkline Pharmaceuticals Ltd(GLAXO) share price is ₹2411.8. It is up 52.94% from its 52 Week Low price of ₹1577
Glaxosmithkline Pharmaceuticals Ltd(GLAXO | Returns |
---|---|
1 Day Returns | 42.15% |
1 Month Returns | -8.31% |
3 Month Returns | -18.08% |
1 Year Returns | 43.2% |